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Abstract
Background: Although it is known that regulatory T cells (Tregs) can suppress the function of effector T cells, and
may contribute to impaired immune response, the precise role of Tregs during the course of hepatitis B virus (HBV)
infection remains to be elucidated. A newly identified subset of the CD4
+Foxp3
+ Tregs, the CD39
+ Tregs, has been
associated with viral infections and autoimmune diseases. Therefore, we hypothesized that this discrete Treg subset
may contribute to the chronic infection of HBV.
Results: Initial characterization studies of healthy peripheral CD39
+FoxP3
+CD4
+ T cells revealed that the majority
were CD45RA
- Treg cells. Subsequent analysis of HBV-infected patients (38 asymptomatic HBV carriers (AsCs), 37
chronic active hepatitis B (CAH), 29 HBV-associated acute-on-chronic liver failure (ACLF)) and healthy individuals (25
controls) was conducted to assess association with HBV copy number and the liver injury marker alanine
aminotransferase (ALT). A higher percentage of CD39
+ Tregs was detected within the population of FoxP3
+CD4
+ T
cells in peripheral blood of AsCs patients. Moreover, the percentage of CD39
+ Tregs was significantly less in CAH
and ACLF patients. The increased proportions of circulating CD39
+ Tregs were positively correlated with serum viral
load, but inversely correlated with serum ALT level.
Conclusion: These findings not only suggest that CD39
+ Treg cells may be involved in HBV disease progression
but also identify CD39
+ Tregs as a dynamic immune regulatory cell population that may represent a new target of
immunomodulatory therapeutic interventions.
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Background
Hepatitis B virus (HBV) is a non-cytopathic, hepatotropic
DNA virus that is capable of inducing necro-inflammatory
liver disease with varying severity. Persistent infection by
HBV is often associated with chronic liver disease, which
can further lead to the development of cirrhosis and hepa-
tocellular carcinoma [1,2]. While many of the underlying
mechanisms of HBV infection progression have been
described, the complex array of pathogen-host interactions
is not yet fully understood. A growing body of recent evi-
dence has suggested that CD4
+CD25
+Foxp3
+ regulatory
T cells (Tregs) may play an important role in the suppres-
sion of antiviral T cell responses during the chronic phases
of HBV infection [3,4]. Some studies have demonstrated
that HBV carriers have a higher frequency of Tregs in per-
ipheral blood and liver than healthy controls or individuals
with resolved infection, indicating that Tregs may contri-
bute to HBV persistence [5-8]. However, other studies
have failed to detect any differences in Treg frequencies
between asymptomatic carriers( A s C s )a n dh e a l t h yc o n -
trols [9]. Thus, the role of Tregs in the progression of liver
disease remains controversial, and little is known about
whether their potential roles in viral hepatitis pathogenesis
differ according to their functional activities.
The largely discordant results among the studies that
have assessed the role of Tregs in HBV infection may
reflect variation in study design and model systems. For
example, the definition of Tregs varied between studies,
and in many was based solely upon the co-expression of
CD4
+ and CD25
highFoxp3
+.U n l i k et h eT r e g si nm i c e ,
human Tregs are heterogeneous and the population exhi-
bits considerable diversity. Phenotypically and functionally
distinct subsets of Tregs can mediate immune suppression
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any medium, provided the original work is properly cited.through distinct mechanisms, including specific profiles of
immunomodulatory factors, such as IL-10, TGF-b,g r a n -
z y m eB ,p e r f o r i n ,C T L A - 4 ,G I T R ,a n dL a g - 3[ 1 0 - 1 2 ] .I n
addition, CD39-mediated interactions were recently impli-
cated in Treg activities during different stages of viral
infection [11,13-15].
CD39 is a recently described molecule with immunomo-
dulatory properties, and is expressed on human and mur-
ine Tregs. Several studies have identified the CD39/
NTPDase1 molecule as a useful biomarker of a CD4
+-
FoxP3
+ regulatory suppressor T cell population with
potent immunosuppressive activity in humans and mice
[16,17]. Notably, a significant increase of CD39 expression
on Tregs has been observed in cancer patients and
patients with human immunodeficiency virus (HIV) infec-
tion, and a strong association was found between CD39
expression on Tregs and tumor or AIDS disease progres-
sion [13-15,18]. Decreased frequency and function of
CD39
+ Tregs have been reported in multiple sclerosis
[19], ryegrass allergy [20], and vascular inflammation after
transplantation [21].
Although the critical roles of CD39 in some diseases
have been described, the potential roles of CD39-expres-
sing Treg cells in hepatitis B pathogenesis have yet to be
elucidated. Therefore, this study was designed to investi-
gate the phenotype characteristics and frequency of per-
ipheral and intrahepatic Tregs and CD39
+ Tregs in
hepatitis B patients, and to determine whether the char-
acteristics of this subset are related to the HBV disease
process.
Methods
Patients and healthy controls
Heparinized peripheral blood samples were obtained from
25 healthy individuals (controls) and 104 HBV-infected
patients, including 38 AsCs, 37 chronic active hepatitis
(CAH) and 29 HBV-associated acute-on-chronic liver fail-
ure (ACLF), all of whom were diagnosed according to the
described criteria [22] (Table 1). Patients co-infected with
HIV, hepatitis A virus, hepatitis C virus (HCV), or hepati-
t i sDv i r u sa n dp a t i e n t sw i t ha resolved viral hepatitis
(other than HBV) were excluded from this study. Patients
and controls who were immunocompromised or pregnant
and patients that received antiviral or immunomodulatory
HBV treatment at any time during the six months prior to
blood sampling were also excluded.
Liver samples were obtained by diagnostic liver needle-
b i o p s ya n di m m e d i a t e l yf r o z e ni nl i q u i dn i t r o g e nu n t i l
analysis. HBV-infected liver tissue samples were obtained
from distal liver tissue of the liver hemangioma patients
with HBV infection. The degree of hepatic inflammation
was graded using the modified histological activity index
(HAI) described by Scheuer [23]. All samples were col-
lected with the informed consent of the patients, and the
experiments were approved by the ethics committee of
the Third Military Medical University (Chongqing,
China).
The clinical and immunological characteristics of the
cohort are shown in Table 1.
Flow cytometric (FCM) analysis and antibodies
The following antibodies were used to detect Treg subsets
by FCM: anti-hCD4, anti-hCD3, anti-hCD45, anti-hCD25,
anti-hCD45RA, anti-hCD39, anti-HLA-DR, anti-Ki-67,
anti-FoxP3, anti-CTLA-4, and anti-IL-17A. All antibodies
were purchased from eBioscience (San Diego, USA),
except for anti-hCD39-FITC (Ancell, USA), anti-hCTLA-4
and -hIFN-g (BD Biosciences, USA).
Peripheral blood mononuclear cells (PBMCs) or liver
infiltrating lymphocytes (LILs) were obtained by Ficoll
gradient and the cells were then stained following the
protocol described in a previous study [6]. The usage of
all antibodies for FCM staining followed the recom-
mended condition by the manufactures. For detection of
intracellular cytokines, CD4
+ T cells were stimulated
with 50 ng/mL phorbol 12-myristate 13-acetate (PMA;
Sigma-Aldrich, USA) and 1 μg/mL ionomycin (Sigma-
Aldrich) in the presence of Golgi-Stop (BD Biosciences)
for 5 hr, and then stained with anti-hIFN-g or anti-hIL-
17A after fixation and permeabilization. Immunoreactive
data was acquired by a FACS CanTo II flow cytometer
(BD Biosciences) and analyzed with Flowjo software
(Tree Star Inc., Canada).
Cell sorting
CD4
+CD25
+ (> 90%) and CD4
+CD25
- (> 90%) T cells
were isolated from PBMCs of healthy controls by using
the CD4
+CD25
+ regulatory T cell isolation kit (Miltenyi
Biotec, USA), according to the manufacturer’si n s t r u c -
tions. CD4
+CD25
+ T cells were then stained with CD39-
APC, CD25-PE, and CD4-PerCP-Cy5.5, respectively.
Finally, CD4
+CD25
+CD39
+ and CD4
+CD25
+CD39
- Treg
cell subsets were sorted using a FACSAria flow cytometer
(BD Biosciences).
Suppression assay
FACS-sorted CD4
+CD25
+CD39
+ or CD4
+CD25
+CD39
-
“suppressor” T cells were first cocultured in triplicate
with autologous CD4
+CD25
- “responders” (10,0000 cells/
well) in 96-well plates at the indicated suppressor/
responder (S/R) ratios for three days with media alone,
or 1 μg/mL plate-bound anti-CD3 (clone UCHT1; BD
Pharmingen) with 2 μg/mL anti-CD28 (clone CD28.2;
BD Pharmingen). Then, the cells were cultured for 16 h
with [
3H] thymidine (1 Ci/well) [24]. After harvesting the
cell cultures and plating onto glass fiber filters, the radio-
activity that had incorporated into the cells’ DNA was
measured as an indicator of cell proliferation by using a
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Inc., USA).
Immunohistochemistry analysis
Fresh liver biopsy specimens were embedded in the OCT
compound (Tissue Tek, Japan) and stored at -80°C until
use. Sections were then incubated with anti-hCD39 (1:50;
eBioscience) or anti-hFoxP3 (1:50; eBioscience). After
washing, sections were incubated with a secondary poly-
meric, peroxidase-labeled rabbit anti-mouse antibody
(EnVision™ System; Dako, Denmark) for 30 min. Sections
that were incubated with isotype- and concentration-
matched immunoglobulin only, without primary antibo-
dies, were used as isotype controls. Reactivity was detected
with a DAB Elite kit (K3465; Dako) and brown coloration
of tissues represented positive staining.
Immunofluorescence staining for human CD4/FoxP3/
CD39 was performed as previously described [6]. Briefly,
sections were incubated with anti-CD39 (1:200;
eBioscience), anti-CD4 (1:100; Santa Cruz Biotechnolo-
g i e s ,U S A ) ,o ra n t i - F o x P 3( 1 : 2 0 0 ;A b c a m ,U K ) ,f o l l o w e d
by incubation with Cy3-labeled anti-mouse IgG (1:500),
Cy5-labeled anti-goat IgG (1:500), and Dylight488-
labeled anti-rat IgG (1:200; Zhongshan Goldenbridge
Biotechnology, China). Sections that had been incubated
with the related isotype control antibodies and fluores-
cence-labeled secondary antibodies were used as isotype
controls. Results were analyzed by fluorescence micro-
scopy (Axioplan 2; Zeiss, Germany) and the positively
stained cells were counted in a high-power field (hpf,
×400), according to the described protocols [8].
Virological and immunological assessment
T h el e v e l so fH B s A g ,a n t i - H B s ,a n t i - H B c ,H B e A g ,a n t i -
HBe, anti-HCV, anti-HDV, anti-HGV, and anti-HIV
were measured using commercially available kits (Abbot
Laboratories, USA). HBV-DNA levels were determined
using real-time polymerase chain reaction (Amplicor,
Roche), according to the manufacturer’s instructions.
The threshold of the HBV DNA detection limit was
100 IU/mL.
Statistical analysis
Data analysis was conducted with Prism 5.0 software
(GraphPad Software, San Diego, CA) and R [http://
www.R-project.org/]. When data can not follow Gaus-
sian distribution, Kruskal-Wallis test was selected for
overall comparisons, and post-hoc analysis was per-
formed using the Steel-Dwass test for multiple compari-
sons among the groups. Meanwhile, data distributed as
Gaussian distribution were shown as mean value ± stan-
dard deviation (SD), followed by student’s t test for 2
independent samples or analysis of one way variance
(ANOVA). Correlation analysis was carried out with
Spearman rank correlation test. Presented P values were
deemed significant at or below a 5% level.
Results
CD39 defines a discrete subset of CD4
+Foxp3
+ T cells
Recent data have shown that mouse Tregs constitutively
express CD39 molecules [25], while the proportions of
CD39
+ cells appear highly variable in humans [17,26].
Accordingly, in this study, FCM analysis revealed a high
variance in the frequency of CD4
+ T cells expressing
CD39, which ranged from 1% to 20% among the healthy
donors and HBV-infected subjects (Additional file 1).
Based on the distribution shown in the scatter diagram
for the frequency of CD4
+ T cells expressing CD39, we
subdivided the total cohort into three groups according
the frequency of CD39-expressing CD4
+ Tc e l l s :
CD39low (< 5%), CD39int (5 ~ 10%) and CD39high
(> 10%), in order to characterize the CD39 expression
with disease status in more detail (Figure 1A and Addi-
tional file 1).
Table 1 Clinical characteristics of populations enrolled in the study
Group HC AsCs CAH ACLF
Cases 25 38 37 29
Sex, male/female 14/11 25/13 26/11 23/6
Age, years (range) 28 (18-35) 33 (20-67) 40 (18-62) 39 (23-61)
ALT, U/L < 40 < 40 475 (50-2340) 429 (58-1885)
TBIL, μmol/L ND ND 95.6 (26-412) 439 (239-881)
PTA, % ND ND 94.1 (42.4-167) 34.8 (17.8-68.5)
HBVDNA, copies/mL (range) ND 2.27 × 10
7
(1.78 × 10
3-1.51 × 10
8 )
2.68 × 10
7
(0-5.07 × 10
8 )
3.58 × 10
7
(0-4.64 × 10
8)
HBsAg-positive 0 38 37 29
HBeAg-positive 0 21 15 12
HBeAb-positive 0 17 22 17
HBcAb-positive 0 38 37 29
ND: not determined.
Data are shown as median and range.
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expression and identified four CD4
+ T subsets in each
group: CD39
+Foxp3
+,C D 3 9
-Foxp3
+,C D 3 9
+Foxp3
- and
CD39
-Foxp3
- T cells (Figure 1B). We consistently observed
an increasing trend of the proportion of CD39
+Foxp3
+
Tregs in total Foxp3
+ Tregs in the CD39low (17%),
CD39int (45%) and CD39high (65%) groups (Figure 1B), in
accordance with the hypothesis that the CD39 surface mar-
ker could be used for routine isolation of functional human
Tregs [27]. Since CD39 expression denotes memory CD4
+
T cells [28,29], we theorized that the highly variable
expression of CD39 may affect the memory phenotype of
CD4
+ T cells. Thus, we analyzed the CD45RA expression
on CD39
+CD4
+ T cells. The results showed that the major-
ity of CD39
+CD4
+ T cells were CD45RA
-. Specifically, >
70% proportions of CD39
+CD4
+ T cells (denoting memory
phenotype) were found in each of the CD39low, CD39int
and CD39high groups (Figure 1C).
CTLA-4, Ki-67, and HLA-DR are usually used as the
phenotype markers for Treg cells. Thus, we further
assessed the co-expression of CD39 and these molecules
on FoxP3
+CD4
+ T cells. Results revealed that the indicated
markers expressed on CD39
+ Tregs were higher than those
on the CD39
- Tregs (by ~1-fold) (Figure 2A), suggesting
that CD39
+ Treg cells might be stronger suppressors than
CD39
- Tregs. Functional assays indicated that CD39
+Treg
cells exhibited stronger suppressive ability to inhibit the
proliferation of CD4
+CD25
- T cells at different S/R ratios,
as compared to the CD39
- Treg cells (Figure 2B). Further-
more, such suppressive effects demonstrated a dose-depen-
dent activity because higher S/R ratio correlated with lower
proliferation of the responder cells (Figure 2B).
In addition, we also observed that the CD39 molecule
could be expressed on Th1 and Th17 cells, as indicated
by the CD39int and CD39high groups displaying a small
fraction of CD39
+CD4
+ T cells capable of secreting IFN-g
and IL-17A, respectively (Additional file 2). This finding
further suggested that CD39 might be capable of distin-
guishing Th1 or Th17 cells into different subpopulations
with different functions.
Together, these data demonstrated that although
CD39 expression appears to be highly variable on Treg
Figure 1 CD39 was expressed variably but preferentially on memory Treg cells. PBMCs from healthy donors were stained with anti-CD4,
-CD39, -CD45RA, or -FoxP3 monoclonal antibodies (mAbs) and analyzed by FACS. Dot plots gated on CD4
+ T cells are shown from a
representative sample. (A) Expression of CD39 in the gated CD4
+ T cells of PBMCs. (B) Co-expression of CD39 and FoxP3 in the gated CD4
+ T
cells of PBMCs. Bar graph for (B) shows the percentage of CD39 expression on FoxP3
+CD4
+ T cells. (C) Co-expression of CD39 and CD45RA in
the gated CD4
+ T cells of PBMCs. The bar graph for (C) shows the percentage of CD39 expression on CD45RA
-CD4
+ T cells. *** P < 0.001.
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+Foxp3
+ Treg
cells, namely the CD39
+Foxp3
+ Tregs. Since CD39 is
preferentially expressed by Treg cells, the CD39
+ Treg
cells were subjected to further investigations to deter-
mine their clinical significance in HBV infection.
CD39
+FoxP3
+ Treg populations correlate with hepatitis B
progression
The frequency of total CD39
+CD4
+ T cells in AsCs, CAH
and ACLF patients was examined. Results showed that
there was no difference in the proportion of CD39
expression on CD4
+ T cells in AsCs, CAH and ACLF
patients, as compared to the healthy control (Figure 3A).
We further found that the frequency of total Treg cells
(CD4
+FoxP3
+ T cells) was significantly higher in CAH
and ACLF patients than in normal controls (Figure 3B).
However, the proportion of CD39-expressing Tregs was
more dynamic. The CD39
+Treg proportion was higher in
AsCs patients than in healthy controls (P < 0.05). How-
ever, this proportion decreased significantly (nearly to
the level in healthy controls) in the CAH and ACLF
patients as compared with that in AsCs patients (P <
0.05, respectively) (Figure 3C ) .T h u s ,d i s t i n c t i o no fT r e g
cell subsets based on the combination of CD39 and
FoxP3 expression is a highly informative approach for
assessing the dynamics of Treg cell differentiation under
HBV disease conditions.
Circulating CD39
+ Treg cell level is correlated with HBV
copy number and ALT level, but not with HBeAg
expression
The body of published research to date has yet to consis-
tently demonstrate whether circulating CD4
+CD25
+ Treg
frequency is correlated with HBV replication [3]. There-
fore, we analyzed the correlation between Treg subsets
and HBV copy number by measuring CD39 expression,
serum ALT levels, HBV DNA load, and HBeAg in AsCs,
CHB and ACLF patients, and comparing the results with
those from total FoxP3
+ Treg cells. Results showed that
there were no significant correlations between total
Figure 2 CD39
+ Treg cells display strong suppressive effects and highly express the functional maker. (A) The percentage of CTLA-4,
HLA-DR and Ki-67 expression on CD39
+ or CD39
- Treg cells. Dot plots gated on CD4
+ T cells are shown with representative results. (B)
Proliferative capacities of CD4
+CD25
- responder alone and with autologous FACS-sorted CD4
+CD25
+CD39
+ Tregs or CD4
+CD25
+CD39
- Tregs
subsets following anti CD3/anti-CD28 stimulation at the indicated S/R ratios on day 3. Statistical data are from three separate experiments with
different donors. * P < 0.01, vs. the effects of CD39
+ Tregs at the corresponding S/R ratios.
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+ Tregs and HBV viral copies (r = 0.182, P = 0.188)
(Figure 4A, left panel). In contrast, when the frequency of
Treg cells was analyzed on the basis of CD39 expression,
it was significantly and positively correlated with the col-
lective serum HBV viral copies in all tested hepatitis B
patients (n = 53, r = 0.344, P = 0.012); however, in concrete
disease status, significant correlation was only observed in
AsCs patients (r = 0.685, P = 0.022) (Figure 4A, middle
panel). Moreover, when analysis was performed with the
CD39high/int/low groups, the HBV viral copies were
found to be significantly increased in the CD39high group,
as compared with the CD39low group in all HBV-infected
subjects (P < 0.05) (Figure 4A, right panel).
Next, the correlation between Treg subsets was analyzed
based on CD39 and serum ALT. Similar with the results
described above for the HBV viral copies, there were no
significant correlations found between total FoxP3
+ Tregs
and serum ALT (r = 0.072, P = 0.638) (Figure 4B, left
panel). In contrast, the frequency of CD39
+FoxP3
+ Treg
cells was significantly negatively correlated with serum
ALT in total hepatitis B patients (n = 39, r = 0.344, P =
0.012), and a strong correlation was also observed in CAH
patients (r = 0.508, P = 0.019) (Figure 4B, middle panel).
Further analysis indicated that the serum ALT levels were
increased in the CD39low group, as compared with the
CD39int/high groups in CAH patients (P < 0.05), but not
in the ACLF patients (Figure 4B, right panel).
In addition, we observed that there were no marked dif-
ferences in the frequencies of total FoxP3
+ Tregs or CD39
+FoxP3
+ Tregs between hepatitis B patients with or with-
out serum HBeAg expression (Figure 4C, left and middle
panels). Similar results were observed in the CD39high/
int/low groups (Figure 4C, right panel).
CD39
+ Treg cells accumulate in the livers of CHB patients
Next, the distribution of CD39
+ Treg cells was examined
in HBV-infected livers by FCM analysis and morphologi-
cal observation. The LILs of distal liver tissue (HAI: G3/
S3) from the liver hemangioma patients with HBV infec-
tion were isolated and stained with various antibodies. As
shown in Figure 5A, the CD39
+ Treg subset was detected
in liver tissue by FCM assays. The CD39-expressing
Foxp3
+ Tregs accounted for about 46% of the total Foxp3
+ Tregs, similar to our previous observations. We further
examined the in situ distribution of the CD39
+ Treg sub-
set in the livers of CHB patients by immunohistochem-
ical and immunofluorescence staining techniques.
Results showed that the CD39
+ and Foxp3
+ cells were
mainly localized near the hepatic portal tract (Figure 5B).
Using triple fluorescence staining, we confirmed that
CD39 and FoxP3 expressions co-localized within regions
with partial CD4
+ T cells (Figure 5C), indicating that the
CD4
+FoxP3
+CD39
+ Treg cells did exist in the portal area
of liver tissue and might be involved in hepatitis B patho-
genesis. Quantitative analysis of the positive cells per hpf
in liver portal areas in CAH patients is shown in Figure
5D. Results demonstrated that about 50% of total Foxp3
+
Tregs expressed CD39, in agreement with the observa-
tions from the above-described FACS assay.
Discussion
While it is well-established that Treg cells play a central
role in maintaining immune system balance, the roles of
Treg cells in HBV disease have been largely inconclusive
[30]. Inconsistent study designs and suboptimal defini-
tion of Tregs, such as relying solely on co-expression of
CD4
+ and CD25
hiFoxp3
+ to identify this subset, are the
most likely culprits. In this study, we employed the
CD39/ENTPD1, a newly described ectoenzyme that
mediates regulatory T cell functions, to define the dis-
crete subsets in Foxp3
+CD4
+ Treg cells. We first character-
ized the peripheral and intrahepatic CD39
+FoxP3
+CD4
+ T
cells (CD39
+ Tregs), most of which were found to be
CD45RA
- Treg cells and displayed stronger suppressive
effects than CD39
- Tregs. Then, we exploited this approach
to investigate the role of Tregs in HBV infection and
Figure 3 CD39 expression on Treg cells in HBV disease progression. Scatter plots summarizing flow cytometry data and showing the
percentage of (A) CD4
+ T cells expressing CD39, (B) CD4
+ T cells expressing FoxP3, and (C) FoxP3
+CD4
+ T cells expressing CD39. The horizontal
lines of (A) and (C) indicate the medians, and the horizontal line of (B) indicates the mean value. * P < 0.05; *** P < 0.001.
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+ Tregs are
closely correlated to serum HBV copies and ALT, but not
correlated with HBeAg in CHB patients.
In this study, FACS analysis of a large number of patient
samples revealed a discrete distribution of CD39 expressing
CD4
+ T cells in healthy controls and hepatitis B patients,
which were discernable by their levels of CD39 expression.
Accordingly, the CD39
+CD4
+T cells were categorized
among three groups: CD39low, CD39int, and CD39high.
Furthermore, the three groups showed distinctive
association patterns with hepatitis disease status. Although
we also observed an association between the frequency of
total CD39
+ Treg cells with disease status, the subtypes of
CD39
+CD4
+ T cells provided more detailed information
than the total CD39
+CD4
+ T cells alone. For instance,
when analysis was performed with the CD39high/int/low
groups, the HBV viral copies were found to be significantly
increased in the CD39high group, as compared with the
CD39low group in all HBV-infected subjects; however, the
serum ALT levels were increased in the CD39low group,
Figure 4 The frequency of CD39
+ Treg cells is correlated with HBV copy number and ALT level, but not HBeAg expression.( A )
Correlations are shown between serum HBV loads and total Tregs (left panel) or CD39
+ Tregs (middle panel) in AsCs, CAH and ACLF patients.
The HBV copies in CD39high/int/low groups are summarized in CD4
+ T cells expressing different levels of CD39 molecule (right panel). (B)
Correlations are shown between serum ALT levels and total Tregs (left panel) or CD39
+ Tregs (middle panel) in CAH and ACLF patients. The ALT
levels in CD39high/int/low groups are summarized in CD4
+ T cells expressing different levels of CD39 molecule (right panel). (C) Scatter plot
summarizing flow cytometry data shows the percentage of CD4
+ T cells expressing FoxP3 (left panel) or CD4
+FoxP3
+ T cells expressing CD39
(middle panel) in HBeAg(+)/(-) hepatitis B patients. The percentages of HBeAg(+) or (-) patients of the total patient number in CD39high/int/low
groups are shown in the right panel. Mean values are indicated by the horizontal line. Bars represent mean ± SD. R is the correlation coefficient,
and P-values are shown. * P < 0.05.
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patients.
Friedman and colleagues found that tag-single nucleo-
tide polymorphisms (SNPs) of the rs10748643 genotype
correlated strongly with CD39 expression, whereby GG
was associated with much higher levels than AA (46-77%
increase) and AG carriers displayed intermediate expres-
sion levels in cell lines from subjects with Caucasian/Eur-
opean, Yoruban, Chinese, and Japanese ancestry [31]. In
our study, we also observed a similar phenomenon.
However, further investigations are required to determine
whether the CD39 gene SNP is associated with any of the
three groups (CD39low, CD39int, and CD39high) in this
study. Such research is anticipated to provide further evi-
dence for CD39 as a more suitable marker for Treg cells
in combination with Foxp3.
To date, research has not been able to establish whether
circulating CD4
+CD25
+ Treg frequency is correlated with
HBV replication. By using CD39 to define the conven-
tional Treg cells, we found in this study that an increase in
Figure 5 Liver infiltration of CD39
+ Treg cells in hepatitis B patients. (A) LILs from distal liver tissue of patients with liver hemangioma and
HBV infection (HAI: S3/G3) were stained with anti-CD4, -CD45RA, -FoxP3, or -CD39 mAbs and analyzed by FCM assays. (B) Diagnostic needle-
biopsy liver samples of CHB patients were stained with anti-CD39 or -FoxP3 mAb. # denotes the same region of adjacent sections. (C) Co-
localization of CD4, CD39, and FoxP3 expressions are shown by immunofluorescence in diagnostic needle-biopsy liver samples of CHB patients.
(D) Numbers of CD39
+FoxP3
- /CD39
-FoxP3
+ /CD39
+FoxP3
+ cells in liver portal areas are shown in CAH patients. Each dot represents one
individual. Horizontal bars represent the median positive numbers.
Tang et al. BMC Immunology 2012, 13:17
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+ Tregs occurred in AsCs patients;
however, such an increase did not occur in the total Treg
cells, which was similar to the proportions observed in
healthy controls. Such a scenario demonstrated that CD39
+ Tregs may suppress the HBV-specific CD8
+ CTL effec-
tor function through the CD39/adenosine pathway [32],
thereby maintaining immune tolerance to the invasive
pathogen. This type of immunomodulation would be
expected to further contribute to HBV replication in AsCs
patients, who are characterized by high HBV load and low
or normal serum levels [33,34].
Nikolova and colleagues reported that the Treg-CD39
subset inhibits cytokine production by HIV-specific CD8
+
T cells, an effect which could be partially relieved by pre-
incubation of CD39
+ Tregs with anti-CD39 mAb [13].
Thus, we further analyzed the relationship between the
proportion of CD39
+ Tregs and clinical pathological para-
meters. Statistical analysis showed that the percentage of
CD39
+ Tregs was positively correlated with serum HBV
load, especially in AsCs patients. However, we did not find
any such correlation between HBV load and total Tregs.
Based on the data in this study, there is no significant cor-
relation between HBeAg expression and the frequency of
total Tregs or CD39
+ Tregs. It is possible that the data in
our study, which was obtained from routine clinical tests,
did not represent an absolute quantification of the HBeAg
protein expressions. Therefore, we were limited in our
ability to investigate the relationship between Treg fre-
quency and HBeAg expression in-depth. Our follow-up
studies have been designed to address this issue while
evaluating the potential clinical utility of manipulating
CD39
+ Treg-mediated immunosuppression.
It is widely believed that the stages of CAH and ACLF in
CHB infection are characterized by lower HBV copy num-
ber and higher serum ALT level, the latter of which often
serves as a reliable marker of liver injury. Interestingly, in
this study, we found that an increase in total Tregs was
only observed in CAH and ACLF patients, as compared
with AsCs patients or healthy controls. However, the sig-
nificantly increased frequency of total Tregs showed no
correlation with the increased serum ALT levels in these
patients, thereby indicating that the increment of the total
Tregs might reflect a homeostatic compensatory mechan-
ism against inflammation. Nevertheless, the proportion of
CD39
+ Tregs was found to be decreased in CAH and
ACLF patients, as compared to those in the AsCs patients.
We further observed that the percentage of CD39
+ Tregs
was negatively correlated with serum ALT levels, espe-
cially in CAH patients, which might be due to subtle shifts
in the subset composition of the total Tregs and which
would be most clearly evidenced by the reduced frequency
of CD39
+ Tregs.
It has been speculated that CD39 expression may be
modulated by the inflammatory milieu. In some cases,
this may lead to FoxP3 dysfunction and down-regulation
of functional markers, such as CD39. Such impaired
CD39
+ Treg cells might lose their ability to effectively
hydrolyze extracellular ATP and ADP that is released by
injured cells, thereby also losing their ability to inhibit
the production of IL-17 [35] or other proinflammatory
cytokines, such as IL-1b [33,36]. In a study of hepatic
flares in chronic hepatitis B conducted by Tan et al., no
increases in CD25
+FoxP3
+CD4
+ T cells or CD39
+CD4
+
T cells were observed at any of the time points tested,
suggesting that these cells may not play any role in inhi-
biting HBV-specific T cell responses in vivo [37]. How-
ever, as many non-Treg CD4
+ T cells also express CD39
molecules, it is possible that the role of the CD39
+ Treg
subset was masked. Friedman and colleagues observed
that, under conditions of inflammatory bowel disease,
CD39-null mice suffer more severe injury than wild-type
mice and exhibit a general tendency toward exaggerated
Th1/IFN-g responses [31]. Fletcher and colleagues
reported that CD39
+Foxp3
+ Treg cells can suppress
pathogenic Th17 cells and are impaired in cases of mul-
tiple sclerosis [19]. Collectively, these evidences support
the notion that while CD39
+ Treg cells can mediate
strong inhibitive effects on other immune effector cells
in vivo,t h eC D 3 9
+ Tregs themselves can be modulated
by various inflammatory factors. Loss of CD39 expres-
s i o na n do ft h er e l a t e di m m unosuppresive functions
during an inflammatory flare in CAH and ACLF
patients could explain the negative correlation observed
between the increased ALT levels and decreased CD39
+
Tregs frequency.
Conclusions
In this study, we investigated the phenotype and the sup-
pressive function of the newly identified CD39
+ Tregs in
details. In HBV infected cases, the CD39
+ Tregs propor-
tion was found to be increased in AsCs patients, but
decreased in CAH and ACLF patients. Importantly, the
CD39
+ Treg proportion is positively correlated with HBV
load but inversely correlated with serum ALT level.
These findings indicate that CD39 expression on FoxP3
+
Treg cells is involved in disease progression of HBV
infection, suggesting that CD39
+ Treg populations are
dynamic and can be followed longitudinally, thereby
opening a new avenue towards therapeutic interventions
aimed at modulating Treg functions.
Additional material
Additional file 1: Figure S1 Subdivision of CD4
+ T cells expressing
CD39 molecules. According to the above distribution patterns of the
scatter diagram for the frequency of CD4
+ T cells expressing CD39 in
healthy controls and hepatitis B patients in our study, the total cohort
were subdivided into three groups according to the frequency of CD39-
expressing CD4
+ T cells: CD39low (< 5%), CD39int (5 ~ 10%), and
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Page 9 of 11CD39high (> 10%). The dotted lines indicate the boundaries between
each group.
Additional file 2: Figure S2 CD39
+ CD4
+ T cells may express
proinflammatory cytokines. PBMCs from healthy donors were stained
with anti-CD4, -CD39, -IFN-g, or -IL-17A mAbs and analyzed by FACS. Dot
plots gated on CD4
+ T cells are shown from a representative sample.
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